Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface

被引:216
作者
Dawson, JP
Berger, MB
Lin, CC
Schlessinger, J
Lemmon, MA
Ferguson, KM
机构
[1] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA
[3] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA
关键词
D O I
10.1128/MCB.25.17.7734-7742.2005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Structural studies have shown that ligand-induced epidermal growth factor receptor (EGFR) dimerization involves major domain rearrangements that expose a critical dimerization arm. However, simply exposing this arm is not sufficient for receptor dimerization, suggesting that additional ligand-induced dimer contacts are required. To map these contributions to the dimer interface, we individually mutated each contact suggested by crystallographic studies and analyzed the effects on receptor dimerization, activation, and ligand binding. We find that domain II contributes > 90% of the driving energy for dimerization of the extracellular region, with domain IV adding little. Within domain II, the dimerization arm forms much of the dimer interface, as expected. However, a loop from the sixth disulfide-bonded module (immediately C-terminal to the dimerization arm) also makes a critical contribution. Specific ligand-induced conformational changes in domain II are required for this loop to contribute to receptor dimerization, and we identify a set of ligand-induced intramolecular interactions that appear to be important in driving these changes, effectively "buttressing" the dimer interface. Our data also suggest that similar conformational changes may determine the specificity of ErbB receptor homo- versus heterodimerization.
引用
收藏
页码:7734 / 7742
页数:9
相关论文
共 32 条
[1]   ErbB-targeted therapeutic approaches in human cancer [J].
Arteaga, CL .
EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :122-130
[2]   Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities [J].
Beerli, RR ;
Hynes, NE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6071-6076
[3]   Disabling receptor ensembles with rationally designed interface peptidomimetics [J].
Berezov, A ;
Chen, JQ ;
Liu, QD ;
Zhang, HT ;
Greene, MI ;
Murali, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (31) :28330-28339
[4]   ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface [J].
Berger, MB ;
Mendrola, JM ;
Lemmon, MA .
FEBS LETTERS, 2004, 569 (1-3) :332-336
[5]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[6]   An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors [J].
Burgess, AW ;
Cho, HS ;
Eigenbrot, C ;
Ferguson, KM ;
Garrett, TPJ ;
Leahy, DJ ;
Lemmon, MA ;
Sliwkowski, MX ;
Ward, CW ;
Yokoyama, S .
MOLECULAR CELL, 2003, 12 (03) :541-552
[7]  
CANTOR CR, 1980, BIOPHYS CHEM TECHNIQ
[8]   Structure of the extracellular region of HER3 reveals an interdomain tether [J].
Cho, HS ;
Leahy, DJ .
SCIENCE, 2002, 297 (5585) :1330-1333
[9]   Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J].
Cho, HS ;
Mason, K ;
Ramyar, KX ;
Stanley, AM ;
Gabelli, SB ;
Denney, DW ;
Leahy, DJ .
NATURE, 2003, 421 (6924) :756-760
[10]   Predictive factors for epidermal growth factor receptor inhibitors - The bull's-eye hits the arrow [J].
Dancey, JE .
CANCER CELL, 2004, 5 (05) :411-415